Search Result
Gene Summary for MIR335 Gene
| Official Symbol |
MIR335 |
Gene Type |
miRNA |
| Full Name |
microRNA 338 |
Entrez |
442906
|
| Ensembl ID |
ENSG00000283604 |
HGNC |
31775
|
| Aliases |
MIRN338, hsa-mir-338, mir-338
|
Chromosome Location |
Chromosome 17, NC_000017.11 (81125883..81125949, complement)
|
| Expression |
-
|
| Summary |
microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop. [provided by RefSeq, Sep 2009]
|
Paper for MIR335 Gene
| PMID |
Author |
Year |
ID in Paper
|
Conclusion |
| 21822301 |
Y Xu |
2012 |
MiR-335 |
miR-335 might function as a metastasis suppressor in gastric cancer by targeting SP1 directly and indirectly through the Bcl w-induced phosphoinositide 3-kinase-Akt-Sp1 pathway. miR-335 showing altered expression at different stages of gastric cancer could be a target for gastric cancer therapies and could be further developed as a potential prognostic factor. |
| 21822301 |
Y Xu |
2012 |
MiR-335 |
miR-335 might function as a metastasis suppressor in gastric cancer by targeting SP1 directly and indirectly through the Bcl w-induced phosphoinositide 3-kinase-Akt-Sp1 pathway.miR-335 showing altered expression at different stages of gastric cancer could be a target for gastric cancer therapies and could be further developed as a potential prognostic factor. |
Experiment for MIR335 Gene
| Sample Type |
Sample Number GC |
Sample Number nonGC |
Method |
Region |
Hpylori |
Normal vs. GC |
Early-stage vs. Advanced stage |
Biological Functions in GC Cells |
Result |
PMID |
| tissue |
70 |
70 |
qRT-PCR |
China |
No Reports |
No |
Down |
- |
Low expression of miR-335 was significantly associated with lymph-node metastasis, poor pT stage, poor pN stage and invasion of lymphatic vessels. Patients with a better pT stage or pN stage had significantly higher miR-335 expression. Patients with a low expression of miR-335 tended to have metastasis invasion into lymphatic vessels. |
21822301 |
| cell line |
- |
- |
Cell invasion assay; Tumor metastasis formation assay; MTT proliferation assay |
- |
No Reports |
- |
- |
miR-335 suppresses gastric cancer invasion and metastasis in vitro, but has no significant effects on cell proliferation of gastric cancer |
miR-335 suppresses gastric cancer invasion and metastasis in vitro, but has no significant effects on cell proliferation of gastric cancer |
21822301 |
| cell line |
- |
- |
Luciferase reporter assay |
- |
No Reports |
- |
- |
miR-335 suppresses gastric cancer invasion and metastasis by targeting Bcl-w and SP1 |
SP1 and Bcl-w are direct targets of miR-335. miR-335 suppresses gastric cancer invasion and metastasis by targeting Bcl-w and SP1 |
21822301 |
Function for MIR335 Gene
| Functional Type |
AUC |
Overall Survival |
Disease-free Survival |
| target |
- |
- |
- |
Interaction for MIR335 Gene
| Interaction Gene |
Method |
PMID |
|
Bcl-w; SP1 |
Luciferase reporter assay |
21822301
|
|
